Grifols, S.A. (FRA:G0FB)

Market Cap	6.57B +18.1%
Revenue (ttm)	7.52B +7.3%
Net Income	372.72M +130.8%
EPS	0.55
Shares Out	n/a
PE Ratio	17.62
Forward PE	10.80
Dividend	0.12 (1.63%)
Ex-Dividend Date	Aug 12, 2025

Volume	n/a
Average Volume	77
Open	7.65
Previous Close	7.65
Day's Range	7.65 - 7.65
52-Week Range	5.75 - 9.55
Beta	n/a
RSI	49.86
Earnings Date	Feb 25, 2026

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1909
• Employees: 23,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: G0FB

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.